Chemistry:Solbinsiran
From HandWiki
Short description: Small interfering RNA therapy
Clinical data | |
---|---|
Other names | LY3561774; LY-3561774 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Solbinsiran is a GalNAc conjugated small interfering RNA therapy that targets angiopoietin-like 3. It is developed by Eli Lilly and Company to reduce the level of apolipoprotein B and reduce the risk of cardiovascular disease.[1][2][3]
References
- ↑ Dudek, Hank; Abrams, Marc; Saxena, Utsav; Turanov, Anton; Brown, Bob; Ruotolo, Giacomo; Michael, Laura (2023-11-07). "Abstract 12705: Identification and Characterization of Solbinsiran, a GalNAc Conjugated siRNA Targeting Angiopoietin-Like 3". Circulation (Hagerstown, MD: Lippincott Williams & Wilkins) 148. doi:10.1161/circ.148.suppl_1.12705. https://www.ahajournals.org/doi/abs/10.1161/circ.148.suppl_1.12705. Retrieved 2023-11-24.
- ↑ Biessen, Erik A.L.; Van Berkel, Theo J.C. (December 2021). "N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases". Arteriosclerosis, Thrombosis, and Vascular Biology 41 (12): 2855–2865. doi:10.1161/ATVBAHA.121.316290. PMID 34645280.
- ↑ Carugo, S.; Sirtori, C. R.; Gelpi, G.; Corsini, A.; Tokgozoglu, L.; Ruscica, M. (November 2023). "Updates in Small Interfering RNA for the Treatment of Dyslipidemias". Current Atherosclerosis Reports 25 (11): 805–817. doi:10.1007/s11883-023-01156-5. PMID 37792132.
![]() | Original source: https://en.wikipedia.org/wiki/Solbinsiran.
Read more |